The Phase 2 LiBBY (Life's End Benefits of cannabidiol and tetrahydrocannabinol) trial found an investigational THC-plus-CBD oil eased agitation in late-stage dementia. Benefit appeared by week 2 and lasted through 12 weeks, but serious safety events were higher with treatment. The study focused on 120 people with Alzheimer's or other dementias who had major agitation and qualified for hospice care. According to the Alzheimer's Association AAIC press release, the formula is investigational and not sold in stores, so families cannot get it now AAIC press briefing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who joined and what they received
- How much agitation changed
- What harms appeared
- How to talk with hospice care teams
Who joined and what they received
Pennington Biomedical Research Center reports 120 people joined the study. All had Alzheimer's or another dementia, major agitation, and hospice eligibility or hospice care Pennington trial summary. The Alzheimer's Association AAIC press release says 10 U.S.
sites took part, with visits in homes or residences. One group received placebo. The other received T2:C100, a study-made oral oil with 2 mg THC plus 100 mg CBD twice daily.
How much agitation changed
Georgetown University School of Medicine reports active treatment cut Cohen-Mansfield Agitation Inventory scores by 6.27 points more than placebo by week 2 Georgetown report. The inventory is a standard rating of agitation behaviors. The gap stayed through 12 weeks.
NeurologyLive reports overall improvement reached 83.9% versus 30.5% at week 2 for drug versus placebo. By week 12, the split was 87.2% versus 23.6%. The rating reflects a clinician's overall impression of improvement.
What harms appeared
NeurologyLive reports overall adverse events were similar at 46.7% versus 42.4% for drug versus placebo NeurologyLive analysis. Serious events were higher with active treatment, 23.3% versus 11.9%. Most were serious infections.
More deaths occurred on active treatment. In hospice-eligible patients, infection and death risk weighs heavily. Families should view less agitation alongside this higher serious-event rate.
How to talk with hospice care teams
T2:C100 was made for the study and remains investigational. It is not sold commercially.
Do not swap in dispensary or over-the-counter cannabis. Use the hospice team to review comfort, safety, and current drugs. Ask specific questions at the next visit.
- Bring examples of agitation: shouting, pacing, resisting care, sleepless nights.
- List sedatives, sleep aids, pain drugs, and recent falls or infections.
- Ask what calming steps to try first and when to call urgently.
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: A Source-Checked Research Briefing for Adult Children
- Implementation-Ready Dementia Interventions in the 2026 NIA Report: Why the Findings May Not Change Care Yet for Adult Children
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: What the News Means for Adult Children
